<p>Simcere Pharmaceutical Group Ltd. has entered into a license and collaboration agreement with Boehringer Ingelheim to develop SIM0709, a pre-clinical TL1A/IL23p19 bispecific antibody for the treatment of inflammatory bowel disease (IBD). Under the terms of the agreement, Boehringer Ingelheim receives global rights to the asset, excluding Greater China. Simcere is eligible to receive an upfront payment, as well as milestone payments totaling up to EUR 1,058 million, and royalties on net sales outside Greater China. The partnership aims to accelerate the development of this potential first-in-class treatment to address unmet needs in IBD worldwide. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN71842) on January 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

ARKG

Reuters

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

iShares US Pharma

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

VG Health

ALPS Medical Breakthrough

Simcere Partners with Boehringer Ingelheim to Develop Bispecific Antibody for IBD